RxDoctor Payments Data

Joshua Hourizadeh, DO

Family Medicine · Long Beach, NYNPI 1932410024

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $64,960 of the $89,974 with a category attached, or 72.2%. Genentech USA, Inc. accounts for 80.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $29,690 and has fallen 51.8% since, to $14,320 in 2025. Among family medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$89,974in general payments, 2019–2025

Across 168 payments — averaging $535.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$72K
  • Pfizer$17K
  • AstraZeneca$303
  • Arbor Pharmaceuticals, Inc.$108

What the payments were for

  • Consulting fees$6,8758%
  • Speaking & faculty fees$64,96072%
  • Travel & lodging$14,10716%
  • Food & beverage$4,0314%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech USA, Inc.118$72,122
Pfizer22$17,440
AstraZeneca5$303
Arbor Pharmaceuticals, Inc.23$108

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,974 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$172,305
Medicare patients
1,023
Services billed
2,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lagevrio (Eua)Molnupiravir18$12,092
Mometasone Furoate25$1,301
Fluticasone Propionate79$845
Albuterol Sulfate HfaAlbuterol Sulfate34$802
ValacyclovirValacyclovir Hcl12$697
Levalbuterol Tartrate HfaLevalbuterol Tartrate12$561
Cefdinir39$498
Oseltamivir Phosphate17$419
Mupirocin43$358
Prednisone138$327
Cephalexin59$312
Doxycycline Monohydrate37$295
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst29$271
Methylprednisolone38$231
Azithromycin52$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPaxlovid$17,440$038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Long Beach

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →